microvasculature

Semaxinib (SU5416) 是一种选择性的 VEGFR(Flk-1 KDR) 抑制剂，其 IC50=1.23 μM。

Cyclo(-RGDfK) (Cyclo (-RGDfK)) 是一种选择性整合素αvβ3的有效抑制剂，IC50值为 0.94 nM。它通过与细胞表面的 αvβ3 整合素结合，特异性靶向肿瘤微血管和癌细胞。

STA-9584 is a potent vascular disrupting agent, which exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors. In vitro, 2-methoxy-5-(5-(3,4,5-trimethoxyphenyl)isoxazol-4-yl)aniline (STA-9122) (active metabolite of STA-9584 ) displayed increased potency relative to other tubulin-binding agents and was highly cytotoxic to tumor cells. STA-9584 induced significant tumor regressions in prostate and breast xenograft models in vivo and, in an aggressive syngeneic model, demonstrated superior tumor growth inhibition and a positive therapeutic index relative to combretastatin A-4 phosphate (CA4P).

Cyclo(-RGDfK) TFA 是一种选择性整合素αvβ3的有效抑制剂，其IC50值为 0.94 nM。它通过与细胞表面的 αvβ3 整合素结合，特异性靶向肿瘤微血管和癌细胞。